# Salmedix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/salmedix

- Industry: Biotechnology
- Headquarters: San Diego, US
- Total disclosed funding: $83M
- Latest round: Series C (Mar 30, 2004)
- Investors on record: 17

## About

Salmedix, Inc. is an oncology drug development company. It focuses on the treatment of hematologic malignancies or blood cancers.

## Funding rounds

- Series C, Mar 30, 2004, $45M — Delphi Ventures, InterWest Partners, OrbiMed Advisors, Versant Ventures, Ventures West Capital, Aberdare Ventures, Easton Capital Investment Group, Presidio Partners, Covera Ventures, Alexandria Venture Investments, Quilvest Capital Partners, H.I.G. BioHealth Partners, GeneChem, Biofrontier Partners, ProQuest Investments, Novo Holdings A/S, Clariden Bank
- Series B, Jun 19, 2002, $28M — Delphi Ventures, InterWest Partners, Versant Ventures, Ventures West Capital, Aberdare Ventures, Presidio Partners, Alexandria Venture Investments, GeneChem, Biofrontier Partners, ProQuest Investments
- Series A, Dec 4, 2001, $10M — InterWest Partners, Versant Ventures

## Investors

- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A, Series B, Series C
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B, Series C
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series B, Series C
- Ventures West Capital (https://capitalatlas.ai/funds/ventures-west-capital) — Series B, Series C
- Aberdare Ventures (https://capitalatlas.ai/funds/aberdare-ventures) — Series B, Series C
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B, Series C
- GeneChem (https://capitalatlas.ai/funds/genechem) — Series B, Series C
- Biofrontier Partners (https://capitalatlas.ai/funds/biofrontier-partners) — Series B, Series C
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Easton Capital Investment Group (https://capitalatlas.ai/funds/easton-capital-investment-group) — Series C
- Covera Ventures (https://capitalatlas.ai/funds/covera-ventures) — Series C
- Quilvest Capital Partners (https://capitalatlas.ai/funds/quilvest-capital-partners) — Series C
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series C
- Novo Holdings A/S — Series C
- Clariden Bank — Series C